Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review

Juarez-Garcia, A.; Sharma, Ruchika; Hünger, Matthias; Kayaniyil, Sheena; Penrod, John R.; Chouaïd, C.

doi:10.1016/j.lungcan.2022.03.008

Cited by 16 publications

(16 citation statements)

References 83 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last decade, cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) has revolutionized clinical practice in oncology as an emerging therapeutic approach and ushered in a new era of cancer treatment ( 1 – 3 ). Immunotherapy has been shown to be effective in oncology treatment ( 4 , 5 ), whether used alone or in combination with other anti-tumor methods ( 6 , 7 ), significantly improving the health-related quality of life in cancer patients. However, its efficacy is still limited by the heterogeneity of the patients’ immune response and the heterogeneity among different tumors ( 8 , 9 ), and some patients will experience primary or acquired drug resistance and related adverse events ( 10 , 11 ) during treatment, which greatly hinder the widespread clinical application of anti-tumor immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)

Yang

Zhao

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThere is a crosstalk between gut microbiota (GM) and cancer immunotherapy (CI). The purpose of this study is to use bibliometric analysis to identify the highly cited papers relating to GM/CI and explore the research status and development trends of the GM/CI research.MethodsA literature search regarding GM/CI publications from 2012 to 2021 was undertaken on July 4, 2022. The article titles, journals, authors, institutions, countries, total citations, keywords, and other information were extracted from the Science Citation Index Expanded (SCIE) of Web of Science Core Collection (WoSCC). The Bibliometrix of R package and VOSviewer were used for bibliometric analysis.ResultsA total of 665 papers were extracted. The number of papers has increased rapidly over the past decade, especially after 2018. The United States and China had the most publications and made great contributions to this field. Th5e Univ Texas MD Anderson Canc Ctr and Univ Paris Saclay were absolutely in the leading position in GM/CI. The most influential authors were Zitvogel L and Routy B. Frontiers in Immunology had the most publications and Science had the most total citations. Historical direct citation analysis explained the historical evolution in GM/CI. Highly cited papers and high-frequency keywords illustrated the current status and trends of GM/CI. Four clusters were identified and the important topics included the role of GM and antibiotics in CI, the methods of targeting GM to improve CI outcomes, the mechanism by which GM affects CI and the application of ICIs in melanoma. “Tumor microbiome”, “proton pump inhibitors” and “prognosis” may be the new focus of attention in the next few years.ConclusionThis study filtered global publications on GM/CI correlation and analyzed their bibliometric characteristics, identified the most cited papers in GM/CI, and gained insight into the status, hotspots and trends of global GM/CI research, which may inform researchers and practitioners of future directions.

show abstract

Section: Introductionmentioning

confidence: 99%

Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)

Yang

Zhao

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…e other systematic review and meta-analysis with 66 realworld studies confirmed the benefit of ICIs on survival in patients with pretreated and advanced NSCLC [7]. In view of the promising results of clinical trials, it could be anticipated that the use of ICIs in cancer will be increasing in patients with NSCLC [8].…”

Section: Introductionmentioning

confidence: 94%

“…For patients with resectable NSCLC, a recent meta-analysis showed that neoadjuvant immunotherapy was feasible and safe, with major pathological response achieved in 52% of the patients and a low 30-day mortality of 0.6% [ 6 ]. The other systematic review and meta-analysis with 66 real-world studies confirmed the benefit of ICIs on survival in patients with pretreated and advanced NSCLC [ 7 ]. In view of the promising results of clinical trials, it could be anticipated that the use of ICIs in cancer will be increasing in patients with NSCLC [ 8 ].…”

Section: Introductionmentioning

confidence: 96%

Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis

Zhang

Wang

Tian

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

Statins are suggested to improve cancer survival by possible anti-inflammatory effect. However, it remains unclear if concomitant use of statins could improve the efficacy of immune checkpoint inhibitors (ICIs) in patients with non-small-cell lung cancer (NSCLC). Accordingly, a meta-analysis was performed to systematically evaluate the effect of concomitant statins in NSCLC patients receiving ICIs. Relevant studies were obtained by literature search in PubMed, Embase, and Web of Science databases. A conservative random-effect model was used to combine the results. Eight cohorts including 2382 patients were included. The programmed death-1/ligand-1 inhibitors were used in seven studies; while the cytotoxic T-lymphocyte-associated protein 4 inhibitors were used in the other study. It was shown that concomitant use of statin did not significantly affect the progression-free survival (PFS, hazard ratio (HR): 0.86, 95% confidence interval (CI): 0.70 to 1.07, P = 0.17 ; I2 = 62%) or overall survival (OS, HR: 0.86, 95% CI: 0.74 to 1.01, P = 0.07 ; I2 = 29%) of NSCLC patients receiving ICIs. Subgroup analyses showed consistent results in studies with univariate or multivariate analytic models ( P for subgroup analysis = 0.97 and 0.38 for the outcome of PFS and OS, respectively). In conclusion, concomitant use of statin seemed to have no significant influence on the survival of patients with NSCLC who were treated with ICIs.

show abstract

“…However, due to factors including the exhaustion of T cells, the defect of antigen presentation, the influence of other immune checkpoint molecules and damage to the IFN-γ signaling pathway, the effective rate of ICI therapy rarely exceeds 40%. [6][7][8] Therefore, it is important to apply clinical biomarkers to screen potential beneficiaries of immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

Lin¹,

Fang²,

Cheng³

et al. 2022

JIR

View full text Add to dashboard Cite

Purpose The advent of immune checkpoint inhibitors (ICIs) is a revolutionary breakthrough. However, without the selection of a specific target population, the response rate of ICI therapy in lung adenocarcinoma (LUAD) is low, so a clinical challenge has arisen in effectively using biomarkers to determine which patients can benefit from ICI therapy. Methods In this study, patients were divided according to whether or not nonsynonymous mutations were present in the BCR signaling pathway, and univariate and multivariate Cox regression models were established based on a LUAD cohort treated with ICIs (Miao-LUAD). Then the relationship between the mutation status of the BCR signaling pathway and the prognosis of immunotherapy was examined. Finally, data from The Cancer Genome Atlas (TCGA) LUAD cohort, the Rizvi-LUAD, the Samstein-LUAD, and the Zhujiang Hospital of Southern Medical University LUAD (Local-LUAD) cohort were combined, and the mutation panorama, immunogenicity, tumor microenvironment (TME) and pathway enrichment analysis between the BCR signaling pathway mutant group (BCR signaling MUT) and the BCR signaling pathway wild group (BCR signaling WT) were comprehensively compared. Results It was found that, compared with the BCR signaling WT, the BCR signaling MUT had a significantly improved progression-free survival (PFS) rate and overall survival (OS) rate, higher immunogenicity (tumor mutational burden, neoantigen load, and DNA damage response signaling mutations), and anti-tumor immune microenvironment. Conclusion These results revealed that the mutation state of the BCR signaling pathway has potential as a biomarker to predict the efficacy of ICIs in LUAD.

show abstract

Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review

Cited by 16 publications

References 83 publications

Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)

Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)

Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

Contact Info

Product

Resources

About